Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial-Reference-Cited by-同舟云学术

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

Published:2020-11-22 Issue:1 Volume:73 Page:143-150
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Posada James¹^ORCID,Valadkhan Saba²,Burge Daniel¹,Davies Kristen³,Tarn Jessica³,Casement John³,Jobling Kerry⁴,Gallagher Peter³,Wilson Douglas⁵,Barone Francesca⁶,Fisher Benjamin A.⁷,Ng Wan‐Fai³

Affiliation:

1. Resolve Therapeutics St. Petersburg Florida

2. Case Western Reserve University Cleveland Ohio

3. Newcastle University Newcastle upon Tyne UK

4. Newcastle Biomedical Research Centre and Newcastle upon Tyne Hospital NHS Foundation Trust Newcastle upon Tyne UK

5. Q2 Solutions Morrisville North Carolina

6. University of Birmingham Birmingham UK

7. NIHR Birmingham Biomedical Research Centre University Hospitals Birmingham NHS Foundation Trust, and University of Birmingham Birmingham UK

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41489

Reference28 articles.

1. A five-year prospective study of fatigue in primary Sjögren's syndrome

2. The prevalence of severe fatigue in rheumatic diseases: an international study

3. Fatigue in Sjögren’s syndrome: a search for biomarkers and treatment targets;Bodewes IL;Front Immunol,2019

4. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis

5. Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenesis of Sjögren syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Update on the pathophysiology and treatment of primary Sjögren syndrome;Nature Reviews Rheumatology;2024-07-09

3. Emerging biologic frontiers for Sjogren’s syndrome: Unveiling novel approaches with emphasis on extra glandular pathology;Frontiers in Pharmacology;2024-05-17

4. Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A Randomized Phase 2 Trial of RSLV-132;Clinical Infectious Diseases;2024-05-10

5. Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group;Seminars in Arthritis and Rheumatism;2024-04